J
John L. Darling
Researcher at University of Wolverhampton
Publications - 48
Citations - 1834
John L. Darling is an academic researcher from University of Wolverhampton. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 21, co-authored 46 publications receiving 1598 citations. Previous affiliations of John L. Darling include University of London & University College London.
Papers
More filters
Journal ArticleDOI
Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties.
Nga Chi Yip,Ivo S. Fombon,Peng Liu,Sarah Brown,Kannappan,Angel L. Armesilla,B Xu,Jim Cassidy,John L. Darling,Weiguang Wang +9 more
TL;DR: Disulfiram/copper inhibited BCSCs and enhanced cytotoxicity of PAC in BC cell lines and may be caused by simultaneous induction of ROS and inhibition of NFκB.
Journal ArticleDOI
Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
Peng Liu,Sarah Brown,T Goktug,P. Channathodiyil,Vinodh Kannappan,J-P Hugnot,P-O Guichet,Xiu-Wu Bian,Angel L. Armesilla,John L. Darling,Weiguang Wang +10 more
TL;DR: The findings indicate that the cytotoxicity of DS/Cu and the enhancing effect ofDS/Cu on the cytOToxicity of dFdC in GBM stem-like cells may be caused by induction of ROS and inhibition of both ALDH and the NFkB pathway.
Journal ArticleDOI
Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells
Peng Liu,I S Kumar,Sarah Brown,Vinodh Kannappan,Patricia Erebi Tawari,James Z. Tang,Wen Guo Jiang,Angel L. Armesilla,John L. Darling,Weiguang Wang +9 more
TL;DR: Disulfiram abolished CSC characters and completely reversed PAC and CDDP resistance in MDA-MB-231PAC10 cells, suggesting cancer stem cells may be responsible for acquired pan-chemoresistance.
Journal ArticleDOI
Disulfiram/copper complex inhibiting NFκB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines
Xiaoxia Guo,Bing Xu,Bing Xu,Shuchita Pandey,Elisabeth Goessl,James Brown,Angel L. Armesilla,John L. Darling,Weiguang Wang +8 more
TL;DR: The data from this study indicated that DS may be used in clinic to improve the therapeutic effect of dFdC in breast and colon cancer patients.
Journal ArticleDOI
Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo.
Peng Liu,Zhipeng Wang,Sarah Brown,Vinodh Kannappan,Patricia Erebi Tawari,Wenguo Jiang,Juan M. Irache,James Z. Tang,Stephen T. Britland,Angel L. Armesilla,John L. Darling,Weiguang Wang,Weiguang Wang Wang +12 more
TL;DR: A liposome-encapsulated DS (Lipo-DS) was developed and its anticancer effect and mechanisms in vitro and in vivo showed very strong anticancer efficacy and no significant in vivo nonspecific toxicity was observed.